---
title: "<span style='color:red;'>Moderate-intensity statin + <br> Ezetimibe <br> <span class='small-vs'>vs</span> <br> High-intensity statin</span>"
subtitle: "_Randomised, open-label, non-inferiority trial<br> in ASCVD patients_" 
format: 
  revealjs:
    slide-number: true
    transition: slide
    theme: simple
    footer: RACING
    reference-location: document
    scrollable: true
editor: visual
---

# [Introduction]{style="color:navy;"}

## [Statin]{style="color:#FF6666;"}

<img src="statin_mechanism.png"/>

## [Statin]{style="color:#FF6666;"}

<img src="statin_side.png"/>

## [Ezetimibe]{style="color:#FF6666;"}

<img src="ezetimibe_mechanism.jpg"/>

## [LDL-C]{style="color:#FF6666;"}

<img src="ldl.jpg"/>

# [Previous Studies]{style="color:navy;"}

## [IMPROVE-IT trial]{style="color:#FF6666;"}

### Interventions:

<br>

#### Combination Therapy Group:

-   Ezetimibe 10 mg + Simvastatin 40 mg

#### Monotherapy Group:

-   Simvastatin 40 mg

## [Takeaways]{style="color:#FF6666;"}

<br> - LDL-C Hypothesis<br><br> - Ezetimibe's Role: when added to statin, provides additional cardiovascular benefit

## [HIJ-PROPER trial]{style="color:#FF6666;"}

### Interventions:

<br>

#### Combination Therapy Group:

-   Pravastatin (10–20 mg) + Ezetimibe (10 mg)

#### Monotherapy Group:

-   Pravastatin (10–20 mg) alone.

## [Takeaways]{style="color:#FF6666;"}

- No Significant Difference in Cardiovascular Outcomes
- Different LDL-C target

# [Methods]{style="color:navy;"}

## [Study design]{style="color:#FF6666;"}

-   Multicenter
-   Randomized(stratified by LDL\<100, DM)
-   Open-label
-   Noninferiority trial

## [Procedure]{style="color:#FF6666;"}

<br>

#### Combination Therapy Group:

-   Rosuvastatin 10 mg + Ezetimibe 10 mg

#### Monotherapy Group:

-   Rosuvastatin 20 mg

## [Primary endpoint]{style="color:#FF6666;"}

-   Cardiovascular death
-   Major cardiovascular event
-   Non-fatal stroke

## [Secondary endpoint]{style="color:#FF6666;"}

### Clinical efficacy

-   LDL-C \< 70 mg/dL(post-hoc: 55mg/dL)
-   Composite of all-cause death, major CV event, non-fatal stroke

### Safety

-   Discontinuation, dose reduction caused by intolerance
-   Clinical adverse events

# [Statistical anaylsis]{style="color:navy;"}

## [Superior and Non-inferior]{style="color:#FF6666;"}

<img src="superior.png"/> <img src="noninferior.png"/>

## [Primary objective]{style="color:#FF6666;"}

### Combination therapy's noninferiority <br>on primary endpoint

-   Expected 3YR event rate: 13%, 14% for combination, monotherapy group with **2.0%** non-inferiority margin
-   Lower target that IMPROVE-IT trial(more potent statin)
-   2.0 margin was based on previous meta-analysis with <br> 7.2% relative risk difference(38% of 19%) between <br> moderate vs high statin therapy

## [Secondary objective]{style="color:#FF6666;"}

### Combination therapy's superiority<br>on secondary endpoint

-   Expected 3YR event rate: 70%, 50% for LDL-C \< 70mg/dL
-   80% power, 5% one-sided alpha, 15% dropout rate<br>-\>220 patients required

## [Statistical analysis]{style="color:#FF6666;"}

-   Categorical data: numbers(percentages)
-   Continuous data: mean (SD) or median (IQR)
-   Time-to-event data: Kaplan-Meier method
-   Event rate between two groups: Log-rank test(mean)
-   Hazard ratio: Cox regression analysis(mean)

## [Statistical analysis]{style="color:#FF6666;"}

-   Primary endpoint: UNL of one-sided 95% CI non-inferiority(97.5% post-hoc)<br><br>
-   Secondary endpoint of clinical efficacy: compared by means of log-rank tests

## [Trial profile]{style="color:#FF6666;"}

<img src="trialprofile.png"/>

## [Statistical analysis]{style="color:#FF6666;"}

-   Primary analysis: **ITT population**
-   Sensitivity analysis: **per-protocol population** after excluding patients who were not given allocated therapy
-   Safety outcome assessment
-   Subgroup analysis: age, sex, BMI, HT, DM, CKD, prior MI, stroke, PAD, baseline LDL-C\<100

# [Results]{style="color:navy;"}

## [Baseline characteristic]{style="color:#FF6666;"}

<img src="baseline.png"/>

## [Follow up]{style="color:#FF6666;"}

-   Combination therapy group: 95%, 94%, 93% at 1, 2, 3 years
-   Monotherapy group: 94%, 91%, 90% at 1, 2, 3 years
-   Other CV events were not significantly different

## [Primary endpoint(ITT)]{style="color:#FF6666;"}

::: panel-tabset
### 3-year clinical endpoint

<img src="3yrendpoint.png"/>

### Primary endpoint

<img src="primaryendpoint.png"/>
:::

## [Secondary endpoint: Clinical efficacy]{style="color:#FF6666;"}

<img src="secondaryendpoint.png"/> - With all p\<0.0001 - Post-hoc analysis(LDL-C \< 50mg/dL): 42,45,42% vs 25,29,25%

## [Secondary: Endpoint_Safety]{style="color:#FF6666;"}

<img src="secondaryendpoint2.png"/>

## [Other analysis]{style="color:#FF6666;"}

-   Consistent result in subgroup analysis
-   Consistent result in per-protocol population <img src="subgroupanalysis.png"/>

## [Discussion]{style="color:#FF6666;"}

-   **Combination therapy** was non-inferior to monotherapy in terms of primary endpoint
-   **Combination therapy** led to better LDL control and less discontinuation
-   **Combination therapy** is expected to reduce adverse effect(statin does-dependant)
-   **Combination therapy** could resolve the problem with up-titration statin monotherapy

## [Limits]{style="color:#FF6666;"}

-   Lower than anticipated event rates(13% vs 9%) allowed margin generous CI
-   Comparison of individual clinical outcomes might be difficult due to small number of events
